Cargando…
International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post‐MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee
BACKGROUND: The Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention (TRS2°P), a 0‐to‐9‐point system based on the presence/absence of 9 clinical factors, was developed to classify the risk of major adverse cardiovascular events (MACE) (a composite of cardiovascular death,...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6064832/ https://www.ncbi.nlm.nih.gov/pubmed/29982232 http://dx.doi.org/10.1161/JAHA.117.008426 |
_version_ | 1783342761135570944 |
---|---|
author | Mok, Yejin Ballew, Shoshana H. Bash, Lori D. Bhatt, Deepak L. Boden, William E. Bonaca, Marc P. Carrero, Juan Jesus Coresh, Josef D'Agostino, Ralph B. Elley, C. Raina Fowkes, F. Gerry R. Jee, Sun Ha Kovesdy, Csaba P. Mahaffey, Kenneth W. Nadkarni, Girish Peterson, Eric D. Sang, Yingying Matsushita, Kunihiro |
author_facet | Mok, Yejin Ballew, Shoshana H. Bash, Lori D. Bhatt, Deepak L. Boden, William E. Bonaca, Marc P. Carrero, Juan Jesus Coresh, Josef D'Agostino, Ralph B. Elley, C. Raina Fowkes, F. Gerry R. Jee, Sun Ha Kovesdy, Csaba P. Mahaffey, Kenneth W. Nadkarni, Girish Peterson, Eric D. Sang, Yingying Matsushita, Kunihiro |
author_sort | Mok, Yejin |
collection | PubMed |
description | BACKGROUND: The Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention (TRS2°P), a 0‐to‐9‐point system based on the presence/absence of 9 clinical factors, was developed to classify the risk of major adverse cardiovascular events (MACE) (a composite of cardiovascular death, recurrent myocardial infarction, or ischemic stroke) among patients with a recent myocardial infarction. Its performance has not been examined internationally outside of a clinical trial setting. METHODS AND RESULTS: We evaluated the performance of TRS2°P for predicting MACE in 53 599 patients with recent myocardial infarction in 5 international cohorts from New Zealand, South Korea, Sweden, and the United States participating in the Chronic Kidney Disease Prognosis Consortium. Overall, there were 19 444 cases of MACE across 5 cohorts over a mean follow‐up of 5 years, and the overall MACE rate ranged from 5.0 to 18.4 (per 100 person‐years). The TRS2°P showed modest calibration (Brier score ranged from 0.144 to 0.173) and discrimination (C‐statistics >0.61 in all studies except 1 from Korea with 0.55) across cohorts relative to its original Brier score of 0.098 and C‐statistic of 0.67 in the derived data set. Although there was some heterogeneity across cohorts, the 9 predictors in the TRS2°P were generally associated with higher MACE risk, with strongest associations observed (meta‐analyzed adjusted hazard ratio 1.6–1.7) for history of heart failure, age ≥75 years, and prior stroke, followed by peripheral artery disease, kidney dysfunction, diabetes mellitus, and hypertension (hazard ratio 1.3–1.4). Prior coronary bypass graft surgery and smoking did not reach statistical significance (hazard ratio ≈1.1). CONCLUSIONS: TRS2°P, a simple scoring system with 9 routine clinical factors, was modestly predictive of secondary events when applied in patients with recent myocardial infarction from diverse clinical and geographic settings. |
format | Online Article Text |
id | pubmed-6064832 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-60648322018-08-07 International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post‐MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee Mok, Yejin Ballew, Shoshana H. Bash, Lori D. Bhatt, Deepak L. Boden, William E. Bonaca, Marc P. Carrero, Juan Jesus Coresh, Josef D'Agostino, Ralph B. Elley, C. Raina Fowkes, F. Gerry R. Jee, Sun Ha Kovesdy, Csaba P. Mahaffey, Kenneth W. Nadkarni, Girish Peterson, Eric D. Sang, Yingying Matsushita, Kunihiro J Am Heart Assoc Original Research BACKGROUND: The Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention (TRS2°P), a 0‐to‐9‐point system based on the presence/absence of 9 clinical factors, was developed to classify the risk of major adverse cardiovascular events (MACE) (a composite of cardiovascular death, recurrent myocardial infarction, or ischemic stroke) among patients with a recent myocardial infarction. Its performance has not been examined internationally outside of a clinical trial setting. METHODS AND RESULTS: We evaluated the performance of TRS2°P for predicting MACE in 53 599 patients with recent myocardial infarction in 5 international cohorts from New Zealand, South Korea, Sweden, and the United States participating in the Chronic Kidney Disease Prognosis Consortium. Overall, there were 19 444 cases of MACE across 5 cohorts over a mean follow‐up of 5 years, and the overall MACE rate ranged from 5.0 to 18.4 (per 100 person‐years). The TRS2°P showed modest calibration (Brier score ranged from 0.144 to 0.173) and discrimination (C‐statistics >0.61 in all studies except 1 from Korea with 0.55) across cohorts relative to its original Brier score of 0.098 and C‐statistic of 0.67 in the derived data set. Although there was some heterogeneity across cohorts, the 9 predictors in the TRS2°P were generally associated with higher MACE risk, with strongest associations observed (meta‐analyzed adjusted hazard ratio 1.6–1.7) for history of heart failure, age ≥75 years, and prior stroke, followed by peripheral artery disease, kidney dysfunction, diabetes mellitus, and hypertension (hazard ratio 1.3–1.4). Prior coronary bypass graft surgery and smoking did not reach statistical significance (hazard ratio ≈1.1). CONCLUSIONS: TRS2°P, a simple scoring system with 9 routine clinical factors, was modestly predictive of secondary events when applied in patients with recent myocardial infarction from diverse clinical and geographic settings. John Wiley and Sons Inc. 2018-07-07 /pmc/articles/PMC6064832/ /pubmed/29982232 http://dx.doi.org/10.1161/JAHA.117.008426 Text en © 2018 The Authors and Merck Sharpe & Dohme Corp. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Research Mok, Yejin Ballew, Shoshana H. Bash, Lori D. Bhatt, Deepak L. Boden, William E. Bonaca, Marc P. Carrero, Juan Jesus Coresh, Josef D'Agostino, Ralph B. Elley, C. Raina Fowkes, F. Gerry R. Jee, Sun Ha Kovesdy, Csaba P. Mahaffey, Kenneth W. Nadkarni, Girish Peterson, Eric D. Sang, Yingying Matsushita, Kunihiro International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post‐MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee |
title | International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post‐MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee |
title_full | International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post‐MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee |
title_fullStr | International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post‐MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee |
title_full_unstemmed | International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post‐MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee |
title_short | International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post‐MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee |
title_sort | international validation of the thrombolysis in myocardial infarction (timi) risk score for secondary prevention in post‐mi patients: a collaborative analysis of the chronic kidney disease prognosis consortium and the risk validation scientific committee |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6064832/ https://www.ncbi.nlm.nih.gov/pubmed/29982232 http://dx.doi.org/10.1161/JAHA.117.008426 |
work_keys_str_mv | AT mokyejin internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee AT ballewshoshanah internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee AT bashlorid internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee AT bhattdeepakl internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee AT bodenwilliame internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee AT bonacamarcp internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee AT carrerojuanjesus internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee AT coreshjosef internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee AT dagostinoralphb internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee AT elleycraina internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee AT fowkesfgerryr internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee AT jeesunha internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee AT kovesdycsabap internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee AT mahaffeykennethw internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee AT nadkarnigirish internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee AT petersonericd internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee AT sangyingying internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee AT matsushitakunihiro internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee |